ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

BACKGROUND: An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estimated 30–80% of advanced solid tumors harbor actionable gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kringelbach, Tina, Højgaard, Martin, Rohrberg, Kristoffer, Spanggaard, Iben, Laursen, Britt Elmedal, Ladekarl, Morten, Haslund, Charlotte Aaquist, Harsløf, Laurine, Belcaid, Laila, Gehl, Julie, Søndergaard, Lise, Eefsen, Rikke Løvendahl, Hansen, Karin Holmskov, Kodahl, Annette Raskov, Jensen, Lars Henrik, Holt, Marianne Ingerslev, Oellegaard, Trine Heide, Yde, Christina Westmose, Ahlborn, Lise Barlebo, Lassen, Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948467/
https://www.ncbi.nlm.nih.gov/pubmed/36814246
http://dx.doi.org/10.1186/s12885-023-10632-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948467/
https://www.ncbi.nlm.nih.gov/pubmed/36814246
http://dx.doi.org/10.1186/s12885-023-10632-9

Ejemplares similares